Goldman Sachs analyst James Quigley upgraded Bayer (BAYRY) to Buy from Neutral with a EUR 33 price target The stock’s risk/reward into the second half of 2025 looks positive and catalysts could support a re-rating over the medium term, the analyst tells investors in a research note. The firm says that following a strong start to the year operationally, with cost discipline in Crop and strong momentum in the underlying Pharma business, Bayer may have reached the bottom of the negative earnings revision cycle.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAYRY: